Compare ClearPoint Neuro Inc (CLPT) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while MONDELEZ INTERNATIONAL INC Common Stock trades at $58.71 (market cap $75.48B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 157.7× ClearPoint Neuro Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.4% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | MDLZ | |
|---|---|---|
Market Cap | $478.63M | $75.48B |
Sector | Health | Consumer Staples |
52-Week High | $29.60 | $70.75 |
52-Week Low | $8.66 | $51.51 |
Enterprise Value | $506.63M | $95.58B |
Dividend Yield | — | 3.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
MDLZ trades at $59.86, up 1.75% today, with a neutral technical signal and bullish moving averages. Revenue grew to $38.54B in 2025, though net income fell to $2.45B. The company maintains strong brand innovation with recent product launches and a new CFO appointment. Analysts show strong buy sentiment with a $68.00 consensus target, implying 13.6% upside.
Outlook remains positive driven by consistent earnings beats and brand strength, but risks include margin pressure from input costs and competitive headwinds. The stock offers a balanced opportunity for growth investors seeking stable consumer staples exposure with dividend income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
